Literature DB >> 11196103

Treating glucosphingolipid disorders by chemotherapy: use of approved drugs and over-the-counter remedies.

N S Radin1.   

Abstract

The accumulation of a glucosphingolipid (GSL) in individuals lacking an adequate level of hydrolase activity could be minimized by chemotherapeutic measures that slow the formation of the GSL and stimulate the defective hydrolase. By achieving a balance in the rates of formation and breakdown, one should be able to alleviate the symptoms of excess storage and achieve a satisfactory accommodation. While several drugs seem to be specifically suitable for this purpose, only one of these has been approved for human use. However, less effective drugs and over-the-counter substances are available for human use and may prove satisfactory for a few years until better ones are made available. The proposed materials and the evidence behind the recommendations are presented in this paper.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11196103     DOI: 10.1023/a:1026796200760

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  39 in total

1.  Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death.

Authors:  B Liu; N Andrieu-Abadie; T Levade; P Zhang; L M Obeid; Y A Hannun
Journal:  J Biol Chem       Date:  1998-05-01       Impact factor: 5.157

2.  A ceramide analogue (PDMP) inhibits glycolipid synthesis in fish embryos.

Authors:  B A Fenderson; G K Ostrander; Z Hausken; N S Radin; S Hakomori
Journal:  Exp Cell Res       Date:  1992-02       Impact factor: 3.905

3.  Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells.

Authors:  Y Lavie; H t Cao; A Volner; A Lucci; T Y Han; V Geffen; A E Giuliano; M C Cabot
Journal:  J Biol Chem       Date:  1997-01-17       Impact factor: 5.157

4.  L-cycloserine slows the clinical and pathological course in mice with globoid cell leukodystrophy (twitcher mice).

Authors:  S M LeVine; T V Pedchenko; I G Bronshteyn; D M Pinson
Journal:  J Neurosci Res       Date:  2000-04-15       Impact factor: 4.164

5.  Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.

Authors:  T Cox; R Lachmann; C Hollak; J Aerts; S van Weely; M Hrebícek; F Platt; T Butters; R Dwek; C Moyses; I Gow; D Elstein; A Zimran
Journal:  Lancet       Date:  2000-04-29       Impact factor: 79.321

6.  Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines.

Authors:  B J Maurer; L S Metelitsa; R C Seeger; M C Cabot; C P Reynolds
Journal:  J Natl Cancer Inst       Date:  1999-07-07       Impact factor: 13.506

7.  Perturbations in the control of cellular arachidonic acid levels block cell growth and induce apoptosis in HL-60 cells.

Authors:  M E Surette; A N Fonteh; C Bernatchez; F H Chilton
Journal:  Carcinogenesis       Date:  1999-05       Impact factor: 4.944

8.  Tamoxifen retards glycosphingolipid metabolism in human cancer cells.

Authors:  M C Cabot; A E Giuliano; A Volner; T Y Han
Journal:  FEBS Lett       Date:  1996-09-30       Impact factor: 4.124

9.  Effect of antiprogestins and tamoxifen on growth inhibition of MCF-7 human breast cancer cells in nude mice.

Authors:  M F El Etreby; Y Liang
Journal:  Breast Cancer Res Treat       Date:  1998-05       Impact factor: 4.872

10.  Dexamethasone modulates rat renal brush border membrane phosphate transporter mRNA and protein abundance and glycosphingolipid composition.

Authors:  M Levi; J A Shayman; A Abe; S K Gross; R H McCluer; J Biber; H Murer; M Lötscher; R E Cronin
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

View more
  2 in total

Review 1.  Future perspectives for glycolipid research in medicine.

Authors:  Timothy M Cox
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2003-05-29       Impact factor: 6.237

2.  Review of miglustat for clinical management in Gaucher disease type 1.

Authors:  Can Ficicioglu
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.